Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 7/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391579 | 1.00 | CAPN1 (0.58) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL4400925 | 0.94 | CAPN1 (0.56) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL21457975 | 0.94 | CAPN1 (0.56) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL4394789 | 0.93 | CAPN1 (0.54) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL21458035 | 0.93 | CAPN1 (0.54) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL20834987 | 0.92 | CAPN1 (0.58) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL3840049 | 0.92 | CAPN1 (0.58) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL21457976 | 0.92 | CAPN1 (0.58) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL4392057 | 0.89 | CAPN1 (0.54) | CAPN1PSMB1CTSKCTSLCTSS | |
| SCHEMBL4391906 | 0.86 | CAPN1 (0.62) | CAPN1PSMB1CTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | CAPN1 4158/4885PSMB1 2040/4885CTSK 4322/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | CAPN1 4158/4885PSMB1 2040/4885CTSK 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.